Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.

Dan Morgenstern-Kaplan Samuel A Kareff Asaad Trabolsi Estelamari Rodriguez Harris B Krause Jennifer R RibeiroHeng TanEmmanuel S Antonarakis Emil Lou Misako Nagasaka Sandra Algaze Heinz-Josef LenzStephen V LiuBalazs Halmos Dave S B Hoon Peter Andreas SeeberPatrick C MaWafik S El-Deiry Ari M VanderWalde Gilberto de Lima Lopes

Published in: The oncologist (2024)

TACSTD2 expression is associated with key driver alterations and a more active immune microenvironment, suggesting possible combinatorial strategies with TROP2-targeting ADCs plus immunotherapy in various solid tumors.

Keyphrases

poor prognosis
stem cells
binding protein
long non coding rna
cancer therapy
gene expression
copy number
genome wide